Xenon Pharmaceuticals annual ebitda
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Xenon Pharmaceuticals EBITDA Growth & History (XENE)
Xenon Pharmaceuticals's calculated EBITDA was −$370.5M for fiscal 2025.
View full Xenon Pharmaceuticals company overviewXenon Pharmaceuticals annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$370.5M | −$93.8M | — |
| 2024 | 2024-12-31 | −$276.7M | −$64.7M | — |
| 2023 | 2023-12-31 | −$212.0M | −$84.3M | — |
| 2022 | 2022-12-31 | −$127.7M | −$49.7M | — |
| 2021 | 2021-12-31 | −$78.1M | −$47.4M | — |
| 2020 | 2020-12-31 | −$30.7M | $11.7M | — |
| 2019 | 2019-12-31 | −$42.4M | −$4.9M | — |
| 2018 | 2018-12-31 | −$37.5M | −$5.5M | — |
| 2017 | 2017-12-31 | −$31.9M | −$8.0M | — |
| 2016 | 2016-12-31 | −$24.0M | −$15.6M | — |
| 2015 | 2015-12-31 | −$8.3M | −$20.2M | — |
| 2014 | 2014-12-31 | $11.8M | $1.4M | +13.70% |
| 2013 | 2013-12-31 | $10.4M | $12.8M | — |
| 2012 | 2012-12-31 | −$2.4M | — | — |
Xenon Pharmaceuticals quarterly ebitda
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$122.6M | −$29.0M | — |
| Q1 2026 | 2026-03-31 | −$111.7M | −$39.7M | — |
| Q4 2025 | 2025-12-31 | −$109.2M | −$32.3M | — |
| Q3 2025 | 2025-09-30 | −$95.7M | −$22.7M | — |
| Q2 2025 | 2025-06-30 | −$93.6M | −$25.1M | — |
| Q1 2025 | 2025-03-31 | −$72.1M | −$13.6M | — |
| Q4 2024 | 2024-12-31 | −$76.8M | −$22.5M | — |
| Q3 2024 | 2024-09-30 | −$73.0M | −$19.1M | — |
| Q2 2024 | 2024-06-30 | −$68.5M | −$13.4M | — |
| Q1 2024 | 2024-03-31 | −$58.5M | −$9.8M | — |
| Q4 2023 | 2023-12-31 | −$54.3M | −$11.3M | — |
| Q3 2023 | 2023-09-30 | −$54.0M | −$16.2M | — |
| Q2 2023 | 2023-06-30 | −$55.0M | −$25.1M | — |
| Q1 2023 | 2023-03-31 | −$48.7M | −$31.7M | — |
| Q4 2022 | 2022-12-31 | −$43.0M | −$18.5M | — |
| Q3 2022 | 2022-09-30 | −$37.8M | −$22.4M | — |
| Q2 2022 | 2022-06-30 | −$29.9M | −$7.7M | — |
| Q1 2022 | 2022-03-31 | −$17.0M | −$1.1M | — |
| Q4 2021 | 2021-12-31 | −$24.6M | −$11.8M | — |
| Q3 2021 | 2021-09-30 | −$15.4M | −$5.9M | — |
| Q2 2021 | 2021-06-30 | −$22.3M | −$21.8M | — |
| Q1 2021 | 2021-03-31 | −$15.9M | −$7.9M | — |
| Q4 2020 | 2020-12-31 | −$12.7M | −$1.3M | — |
| Q3 2020 | 2020-09-30 | −$9.5M | −$681,000 | — |
| Q2 2020 | 2020-06-30 | −$479,000 | $9.9M | — |
| Q1 2020 | 2020-03-31 | −$7.9M | $3.8M | — |
| Q4 2019 | 2019-12-31 | −$11.5M | −$3.1M | — |
| Q3 2019 | 2019-09-30 | −$8.8M | $5.2M | — |
| Q2 2019 | 2019-06-30 | −$10.4M | −$3.0M | — |
| Q1 2019 | 2019-03-31 | −$11.7M | −$4.0M | — |
| Q4 2018 | 2018-12-31 | −$8.3M | −$409,000 | — |
| Q3 2018 | 2018-09-30 | −$14.0M | −$5.6M | — |
| Q2 2018 | 2018-06-30 | −$7.4M | $282,000 | — |
| Q1 2018 | 2018-03-31 | −$7.7M | $166,000 | — |
| Q4 2017 | 2017-12-31 | −$7.9M | −$2.6M | — |
| Q3 2017 | 2017-09-30 | −$8.5M | −$1.3M | — |
| Q2 2017 | 2017-06-30 | −$7.7M | −$1.6M | — |
| Q1 2017 | 2017-03-31 | −$7.8M | −$2.4M | — |
| Q4 2016 | 2016-12-31 | −$5.3M | −$3.0M | — |
| Q3 2016 | 2016-09-30 | −$7.2M | −$6.6M | — |
| Q2 2016 | 2016-06-30 | −$6.1M | −$6.6M | — |
| Q1 2016 | 2016-03-31 | −$5.4M | $554,000 | — |
| Q4 2015 | 2015-12-31 | −$2.3M | −$2.6M | — |
| Q3 2015 | 2015-09-30 | −$558,000 | −$9.4M | — |
| Q2 2015 | 2015-06-30 | $484,000 | −$1.1M | −68.83% |
| Q1 2015 | 2015-03-31 | −$5.9M | −$7.1M | — |
| Q4 2014 | 2014-12-31 | $240,000 | — | — |
| Q3 2014 | 2014-09-30 | $8.8M | — | — |
| Q2 2014 | 2014-06-30 | $1.6M | — | — |
| Q1 2014 | 2014-03-31 | $1.2M | — | — |
Xenon Pharmaceuticals ebitda trends
Over the last five fiscal years, Xenon Pharmaceuticals's ebitda decreased from −$30.7M to −$370.5M, a change of −$339.9M. The latest reported quarter, Q2 2026, shows −$122.6M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xenon Pharmaceuticals source filings ↗Community posts
Xenon files its seizure-drug application while pausing new psychiatry enrollment
Xenon ($XENE) submitted a US new-drug application for azetukalner to treat focal seizures, supported by its X-TOLE and X-TOLE2 studies and more than 1,500 patient-years of exposure. Submission is an application milestone, not confirmation t ...
